Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages. The population undergoing low-dose computed tomography (LDCT) screening significantly overlaps with those at high risk for PDAC; however, traditional imaging methods have limited sensitivity for detecting pancreatic lesions. This study utilizes the Pancreatic Cancer Detection with Artificial Intelligence (PANDA) system to enhance LDCT for pancreatic cancer screening in a prospective, multicenter, observational cohort. PANDA will analyze LDCT images, followed by a multidisciplinary team (MDT) reassessment of abnormal interpretations. Based on MDT evaluation, individuals will be recalled for further examination, placed under a personalized follow-up plan, or monitored for at least one year. The primary outcomes include pancreatic cancer detection rate, positive predictive value, consensus rate, and recall rate, while secondary outcomes focus on early-stage cancers, resectable tumors, and safety indicators such as false positive rates and unnecessary procedures. This study aims to assess the effectiveness and safety of AI-assisted LDCT for PDAC detection, providing a practical solution for improving public health and enhancing early diagnostic capabilities.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: t
View:

• Age 50 years and above.

• Voluntary signing of informed consent.

• Completion of LDCT examination.

Locations
Other Locations
China
Jiaxing University Affiliated Second Hospital
RECRUITING
Jiaxing
Ningbo University Affiliated People's Hospital
RECRUITING
Ningbo
Changhai Hospital
RECRUITING
Shanghai
Meinian Onehealth Healthcare Holdings Co., Ltd
RECRUITING
Shanghai
Ruici Medical Examination Institution
RECRUITING
Shanghai
Contact Information
Primary
Wang Bei Lei, M.D.
lilly_wang@126.com
13774238083
Backup
Guo Shi Wei, M.D.
gestwa@163.com
18621500666
Time Frame
Start Date: 2025-08-15
Estimated Completion Date: 2032-12-30
Participants
Target number of participants: 400000
Treatments
AI-powered LDCT (LDCT+AI)
Participants will undergo annual screening with the LDCT+AI system.
Related Therapeutic Areas
Sponsors
Collaborators: Ningbo University Affiliated People's Hospital, Jiaxing University Affiliated Second Hospital, Ruici Medical Examination Institution, Meinian Onehealth Healthcare Holdings Co., Ltd
Leads: Changhai Hospital

This content was sourced from clinicaltrials.gov